AI Science Tracker
EN

Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.

1 discovery from 2023

Discoveries

PLAC8 is an innovative biomarker for immunotherapy participating in remodeling the immune microenvironment of renal clear cell carcinoma.

Source check: Source checked. Not independent scientific confirmation.

Finding: Original full text, Methods/Results: TCGA expression analyses and external cohort support PLAC8 immune associations; cell-line knockdown tested proliferation, migration and invasion. Immune-therapy response is computationally inferred, not demonstrated in a treated cohort. AI role: Machine-learning prognostic model based on PLAC8-related molecules. The article appeared in Frontiers In Oncology.

Technology: Machine-learning prognostic model based on PLAC8-related molecules

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Machine-learning prognostic model based on PLAC8-related molecules
Test and result
Original full text, Methods/Results: TCGA expression analyses and external cohort support PLAC8 immune associations; cell-line knockdown tested proliferation, migration and invasion. Immune-therapy response is computationally inferred, not demonstrated in a treated cohort.
Limitation / still unknown
The result is limited to the described dataset, cohort, experimental system, or validation design; generalization beyond that scope and downstream real-world benefit are not established. Author affiliation was not stated in the reviewed abstract or metadata.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1207551/full · https://europepmc.org/article/MED/38023190 · https://pubmed.ncbi.nlm.nih.gov/38023190/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.